Abivertinib
Abivertinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target tyrosine-protein kinase JAK3, epidermal growth factor receptor, and tyrosine-protein kinase BTK.
| Trade Name | |
|---|---|
| Common Name | Abivertinib |
| Indication | |
| Drug Class | Tyrosine kinase inhibitors: epidermal growth factor receptor (EGFR) inhibitors |
